Compound · clinical trials

Venetoclax clinical trials

Also listed in trial records as ABT-199, Venclyxto, GDC 0199, ABT199, RO5537382, PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine, Venetoclax (ABT-199, 5-Aza-2'-deoxycytidine, RG7601, Venetoclax Product, Venetoclax/Acalabrutinib

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 216 trials in our China, USA, France, Spain, Germany, Israel, Australia, Canada, Italy, UK, Belgium, Poland, Czechia, Denmark, Netherlands, Japan, South Korea, Sweden, Austria, Mexico, Brazil, Taiwan, Turkey, Norway, Switzerland, Ireland, Portugal, Singapore, Egypt and India registers that name Venetoclax as an intervention. Synced 9 Nov 2026

216Current trials

130Recruiting now

105Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Venetoclax is named as an intervention in 216 current clinical trials in our China, USA, France, Spain, Germany, Israel, Australia, Canada, Italy, UK, Belgium, Poland, Czechia, Denmark, Netherlands, Japan, South Korea, Sweden, Austria, Mexico, Brazil, Taiwan, Turkey, Norway, Switzerland, Ireland, Portugal, Singapore, Egypt and India registers. 130 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (22). The most-studied condition is Acute Myeloid Leukemia. The EU clinical trials register (CTIS) separately lists 12 authorised or ongoing trials, 1 with a site in Ireland.

Venetoclax also has an approved-drug profile on this site (FDA label data): Venclexta (Venetoclax) →

Where Venetoclax is approved

All regulators →

Of the three regulators tracked here, the first to approve Venetoclax was the US, on 11 Apr 2016. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

11 Apr 2016

Venclexta

NDA208573 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

4 Dec 2016

Venclyxto

EMA product page

First centralised authorisation

CACanada (Health Canada)

30 Sep 2016

Venclexta

Notice of Compliance 18536

First new-drug NOC

4 EU orphan designations, most recently for treatment of mantle cell lymphoma (12 Dec 2017, withdrawn)
1 EU safety letter (DHPC), latest: type ii variation for Venclyxto, 10 Jun 2021

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Venetoclax patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Venetoclax, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Venclexta

10 listed patents; the last listed expires 6 Sep 2033 (US 9539251).
Latest patent on the drug substance itself: 29 Jan 2032 (US 8722657).

See the Orange Book listing for NDA 208573

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Venetoclax

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$45.6m

5,263 prescriptions in 2025 · Venclexta

+4% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Venetoclax works

All drug targets →

Apoptosis regulator Bcl-2 inhibitor Inhibitor
Target: BCL2 BCL2 apoptosis regulator
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on BCL2

Lisaftoclax Navitoclax

Diseases it has been tested for in clinical trials, by furthest phase

T-cell acute lymphoblastic leukemiaPhase 3
T-cell adult acute lymphocytic leukemiaPhase 3
Acute leukemiaPhase 3
Acute lymphoblastic leukemiaPhase 3
Acute myeloid leukemiaPhase 3
LeukemiaPhase 3
Mantle cell lymphomaPhase 3
Myelodysplastic syndromePhase 3
Plasma cell myelomaPhase 3
Myeloid neoplasmPhase 2/3

70 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3137309, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 8318, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Venetoclax

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 7 technology appraisals of Venetoclax. 6 are current, and 6 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia NICE TA1119	Recommended	7 Jan 2026	Current
Venetoclax for treating chronic lymphocytic leukaemia NICE TA796	Recommended	15 Jun 2022	Current
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable NICE TA787	Optimised	27 Apr 2022	Current
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable NICE TA765	Recommended	2 Feb 2022	Current
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia NICE TA663	Optimised Recommended (Cancer Drugs Fund)	9 Dec 2020	Current
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia NICE TA561	Recommended	27 Feb 2019	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Venetoclax

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 3 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Venclyxto
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Venetoclax

ATC code: L01XX52
ChEMBL: CHEMBL3137309
DrugBank: DB11581
PubChem CID: 49846579
CAS number: 1257044-40-8
FDA UNII: N54AIC43PW
Wikidata: Q23671272
Wikipedia: Venetoclax

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting13060%
Not yet open157%
Active, closed7032%
By invitation10%

Trials by phase

Phase 29042%
Phase 33818%
Phase 1/23014%
Phase 1199%
Not applicable188%
Phase 2/3136%
Phase 442%
Observational31%
Early Phase 110%

Clinical trials of Venetoclax

216 trials

Study	Phase	Status	Lead sponsor	Registers
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR NCT06571825 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 4	Recruiting	He Huang	China
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India NCT07044687 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 4	Recruiting	AbbVie	India
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 NCT04628026 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 3	Recruiting	University of Ulm	Germany, Netherlands, Belgium, Austria, Norway
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL NCT05197192 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia	Phase 3	Recruiting	German CLL Study Group	Germany
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). NCT05947851 · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, Brazil, Mexico, Japan, Taiwan, Australia, Israel
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL NCT06361329 · ClinicalTrials.gov ↗ · ETP-ALL	Phase 3	Recruiting	First Affiliated Hospital of Zhejiang University	China
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) NCT06428019 · Chronic Lymphocytic Leukemia	Phase 3	Recruiting	AbbVie	UK, USA, China, France, Spain, Taiwan, Australia
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment NCT06496308 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL)	Phase 3	Recruiting	Ruijin Hospital	China
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors NCT06846671 · CLL, Chronic Lymphocytic Leukemia	Phase 3	Recruiting	BeOne Medicines	UK, USA, Germany, Italy, Netherlands, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Australia
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) NCT06852222 · Leukemia, Myeloid, Acute	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel, Egypt
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Recruiting	BeOne Medicines	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Australia, Israel
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia NCT06990321 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Elderly	Phase 3	Recruiting	Yehui Tan	China
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312 · Acute Myeloid Leukemia (AML)	Phase 3	Recruiting	Kura Oncology, Inc	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Portugal, Canada, Mexico, South Korea, Taiwan, Australia
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients NCT07132684 · ClinicalTrials.gov ↗ · AML, Adult	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia NCT07277231 · Chronic Lymphocytic Leukemia	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Czechia, Canada, Brazil, South Korea, Australia
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial NCT07396480 · ClinicalTrials.gov ↗ · Venentoclax, Myeloid Malignancies, Conditioning	Phase 3	Recruiting	First Affiliated Hospital of Zhejiang University	China
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) NCT07478991 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Adult	Phase 3	Recruiting	PETHEMA Foundation	Spain
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia NCT07514936 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients	Phase 3	Recruiting	Chinese PLA General Hospital	China
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML NCT07539818 · ClinicalTrials.gov ↗ · AML	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR NCT02416388 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 2/3	Recruiting	University Hospital, Angers	France
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment NCT03868722 · ClinicalTrials.gov ↗ · CLL	Phase 2/3	Recruiting	Copenhagen University Hospital, Rigshospitalet	Netherlands, Sweden, Denmark
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) NCT04256317 · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm	Phase 2/3	Recruiting	Taiho Oncology, Inc	UK, USA, Germany, France, Spain, Italy, Poland, Czechia, Canada
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission NCT05404906 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML) in Remission	Phase 2/3	Recruiting	The First Affiliated Hospital of Soochow University	China
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML NCT05805098 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2/3	Recruiting	The First Affiliated Hospital of Soochow University	China
VA vs DA for Newly Diagnosed Hig-risk AML NCT05939180 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2/3	Recruiting	The First Affiliated Hospital of Soochow University	China
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Newly-diagnosed Pediatric T-cell ALL Protocol NCT06855810 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	Phase 2/3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation NCT06972641 · ClinicalTrials.gov ↗ · AML, MDS	Phase 2/3	Recruiting	Ruijin Hospital	China
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia NCT07255872 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) NCT07581002 · Acute Myeloid Leukemia	Phase 2/3	Recruiting	AbbVie	USA, China, France, Spain, Austria, South Korea, Taiwan, Israel
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) NCT04523428 · ClinicalTrials.gov ↗ · CLL/SLL	Phase 2	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands, Belgium, Denmark
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) NCT04758975 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL)	Phase 2	Recruiting	Paolo Ghia	Italy
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) NCT04895436 · Chronic Lymphocytic Leukemia (CLL)	Phase 2	Recruiting	AbbVie	UK, USA, Germany, Spain, Italy, Austria, Brazil, Australia, Israel
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms NCT05074355 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasm	Phase 2	Recruiting	University Health Network, Toronto	Canada
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia NCT05099471 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia, Treatment Naive	Phase 2	Recruiting	Christian Buske	Germany
Zanubrutinib and Venetoclax in CLL (ZANU-VEN) NCT05168930 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)	Phase 2	Recruiting	Dana-Farber Cancer Institute	Israel
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling NCT05431257 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Copenhagen University Hospital, Rigshospitalet	Denmark
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) NCT05554393 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) NCT05554406 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) NCT05564390 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia NCT05566054 · ClinicalTrials.gov ↗ · Acute Monocytic Leukemia, Newly Diagnosed	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia NCT05660473 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer NCT05725200 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Oslo University Hospital	Norway
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia NCT05736965 · ClinicalTrials.gov ↗ · AML, Adult	Phase 2	Recruiting	Shanghai Tong Ren Hospital	China, Japan
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results NCT05736978 · ClinicalTrials.gov ↗ · AML, MRD	Phase 2	Recruiting	Shanghai Tong Ren Hospital	China
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia NCT05881265 · ClinicalTrials.gov ↗ · APL	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Venetoclax Combined With Azactidine in the Treatment of ALAL NCT05901974 · ClinicalTrials.gov ↗ · Acute Leukemia of Ambiguous Lineage	Phase 2	Recruiting	Sheng-Li Xue, MD	China
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML NCT05904106 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Technische Universität Dresden	Germany
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML NCT06014489 · ClinicalTrials.gov ↗ · AML, Adult	Phase 2	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT06084819 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukemia	Phase 2	Recruiting	Chinese PLA General Hospital	China
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma NCT06115135 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory	Phase 2	Recruiting	Oncotherapeutics	USA
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML NCT06156579 · ClinicalTrials.gov ↗ · AML, MDS	Phase 2	Recruiting	University Hospital Tuebingen	Germany
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML NCT06191263 · Acute Myeloid Leukemia	Phase 2	Recruiting	Ryvu Therapeutics SA	France, Spain, Italy, Poland
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML NCT06221683 · ClinicalTrials.gov ↗ · AML, Childhood, Acute Myeloid Leukemia	Phase 2	Recruiting	Children's Hospital of Soochow University	China
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) NCT06317649 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL NCT06387121 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT NCT06447090 · ClinicalTrials.gov ↗ · Relapse Acute Myeloid Leukemia	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML NCT06451861 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma NCT06471738 · ClinicalTrials.gov ↗ · Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma	Phase 2	Recruiting	Chinese PLA General Hospital	China
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma NCT06510309 · ClinicalTrials.gov ↗ · Lymphoma, Marginal Zone Lymphoma, MZL	Phase 2	Recruiting	Gottfried von Keudell, MD PhD	Israel
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS NCT06536959 · ClinicalTrials.gov ↗ · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes	Phase 2	Recruiting	Beijing 302 Hospital	China
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia NCT06537843 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Hospital Municipal São José	Brazil
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL NCT06554626 · ClinicalTrials.gov ↗ · Precursor B-Cell Lymphoblastic Leukemia	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients NCT06557421 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Institut Paoli-Calmettes	France
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma NCT06558604 · ClinicalTrials.gov ↗ · Lymphoma, Mantle-Cell	Phase 2	Recruiting	The Lymphoma Academic Research Organisation	France, Belgium
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML NCT06621199 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML NCT06621212 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML NCT06635681 · ClinicalTrials.gov ↗ · AML (Acute Myelogenous Leukemia)	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) NCT06672146 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108 · ClinicalTrials.gov ↗ · T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment NCT06696183 · ClinicalTrials.gov ↗ · AML - Acute Myeloid Leukemia	Phase 2	Recruiting	Technische Universität Dresden	Germany
Venetoclax and Decitabine in R/R T-ALL NCT06712121 · ClinicalTrials.gov ↗ · T Lymphoblastic Leukemia/Lymphoma	Phase 2	Recruiting	Seoul National University Hospital	South Korea
VHAG in Treating R/R T-ALL/LBL NCT06742463 · ClinicalTrials.gov ↗ · Acute T Lymphpblastic Leukemia/Lymphoma	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL NCT06754267 · ClinicalTrials.gov ↗ · Precursor B-Cell Acute Lymphoblastic Leukemia	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) NCT06917911 · ClinicalTrials.gov ↗ · Core Binding Factor Acute Myeloid Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, First Line Therapy	Phase 2	Recruiting	Chinese PLA General Hospital	China
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy NCT06958705 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients NCT07007052 · ClinicalTrials.gov ↗ · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	Phase 2	Recruiting	French Innovative Leukemia Organisation	France
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations NCT07012447 · ClinicalTrials.gov ↗ · Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, Nos	Phase 2	Recruiting	yuejun Liu	China
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease NCT07023588 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 2	Recruiting	Yehui Tan	China
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab NCT07024706 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)	Phase 2	Recruiting	AstraZeneca	Ireland, UK, USA, Spain, Italy, Poland, Austria, Czechia, Brazil
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes NCT07047183 · ClinicalTrials.gov ↗ · Myelodysplastic Neoplasms, Transplantation	Phase 2	Recruiting	Yehui Tan	China
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML NCT07078591 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Beijing 302 Hospital	China
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) NCT07154264 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2	Recruiting	Dizal Pharmaceuticals	China
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients NCT07159620 · ClinicalTrials.gov ↗ · Adult T-cell Leukemia/Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) NCT07231952 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma	Phase 2	Recruiting	Memorial Sloan Kettering Cancer Center	Israel
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS NCT07238686 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes	Phase 2	Recruiting	Beijing 302 Hospital	China
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) NCT07719556 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia NCT07743112 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Maxinovel Pty., Ltd	China
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT03850574 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML	Phase 1/2	Recruiting	Aptose Biosciences Inc	USA, Germany, Spain, South Korea, Australia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma	Phase 1/2	Recruiting	CellCentric Ltd	UK, USA, France, Spain, Sweden
Study to Evaluate the Safety and Tolerability of EP0042 NCT04581512 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes	Phase 1/2	Recruiting	Ellipses Pharma	UK, Netherlands, Australia
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML NCT04588922 · Hematologic Malignancies	Phase 1/2	Recruiting	Sellas Life Sciences Group	USA, China, Egypt
Avo In R/R And Previously Untreated MCL NCT04855695 · Mantle Cell Lymphoma, Refractory Lymphoma	Phase 1/2	Recruiting	Austin I Kim	Israel
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) NCT04988555 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma	Phase 1/2	Recruiting	Sumitomo Pharma America, Inc	UK, USA, France, Spain, Italy, Belgium, Switzerland, Canada, Japan, South Korea, Taiwan, Singapore
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05211570 · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia	Phase 1/2	Recruiting	AB Science	USA, France, Spain
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART NCT05668026 · HIV-1-infection	Phase 1/2	Recruiting	University of Aarhus	Denmark, Australia
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05745714 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Norway, Israel
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Norway, Israel
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL NCT05791409 · ClinicalTrials.gov ↗ · CLL/SLL	Phase 1/2	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Germany, Netherlands, Belgium, Denmark, Australia
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML NCT05807932 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia	Phase 1/2	Recruiting	Heinrich-Heine University, Duesseldorf	Germany
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS NCT06471946 · ClinicalTrials.gov ↗ · Higher-risk Myelodysplastic Syndromes	Phase 1/2	Recruiting	Navy General Hospital, Beijing	China
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation NCT06561880 · ClinicalTrials.gov ↗ · FLT3 Gene Mutation, AML	Phase 1/2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855 · ClinicalTrials.gov ↗ · CML,Blast Phase	Phase 1/2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML NCT07451912 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML	Phase 1/2	Recruiting	The First Affiliated Hospital of Soochow University	China
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 1/2	Recruiting	Nurix Therapeutics, Inc	USA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Poland, South Korea, Australia
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory	Phase 1	Recruiting	University Hospital, Antwerp	Belgium
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML	Phase 1	Recruiting	Kura Oncology, Inc	USA
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome NCT06501196 · Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute	Phase 1	Recruiting	BlossomHill Therapeutics	USA
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML NCT06634394 · Acute Myeloid Leukemia (AML)	Phase 1	Recruiting	Aptevo Therapeutics	USA
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML NCT07374029 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse	Phase 1	Recruiting	David Avigan	Israel
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study) NCT07481175 · ClinicalTrials.gov ↗ · HIV-1	Phase 1	Recruiting	Thomas Aagaard Rasmussen	Spain, Denmark
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors NCT07713732 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm)	Phase 1	Recruiting	Treeline Biosciences, Inc	Australia
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP NCT06390306 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia	Observational	Recruiting	Peking University People's Hospital	China
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979 · ClinicalTrials.gov ↗ · Amyloidosis; Systemic, AL Amyloidosis	Not applicable	Recruiting	Jin Lu, MD	China
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia NCT06265545 · ClinicalTrials.gov ↗ · AML, Refractory, Relapsed	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia NCT06386302 · ClinicalTrials.gov ↗ · AML, Acute Myeloid Leukemia	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228 · ClinicalTrials.gov ↗ · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL NCT06481241 · ClinicalTrials.gov ↗ · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy NCT06643962 · ClinicalTrials.gov ↗ · Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute	Not applicable	Recruiting	Affiliated Hospital of Nantong University	China
MRD-positive AML Clinical Study NCT07131059 · ClinicalTrials.gov ↗ · AML, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) NCT07183878 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes	Not applicable	Recruiting	First Affiliated Hospital of Zhejiang University	China
Maintenance Venetoclax in AML Fit Patients NCT07244367 · ClinicalTrials.gov ↗ · Acute Myeloid Leukaemia (AML)	Not applicable	Recruiting	Sohag University	Egypt
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL NCT07454226 · ClinicalTrials.gov ↗ · Ph-Like, Acute Lymphoblastic Leukemia	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML NCT07490288 · ClinicalTrials.gov ↗ · AML	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL NCT07493161 · ClinicalTrials.gov ↗ · Ph+ ALL	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia NCT07495631 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML NCT06763666 · ClinicalTrials.gov ↗ · Relapsed/Refractory AML	Phase 4	Not yet open	Nanfang Hospital, Southern Medical University	China
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction NCT07082452 · ClinicalTrials.gov ↗ · Leukemia, B-Cell, Chronic, Leukemia	Phase 3	Not yet open	Gustave Roussy, Cancer Campus, Grand Paris	France
VAH vs VA in Newly Diagnosed Elderly AML NCT07469046 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)	Phase 3	Not yet open	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML NCT07486479 · Acute Myeloid Leukemia (AML)	Phase 3	Not yet open	The First Affiliated Hospital of Soochow University	China
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT NCT06765928 · ClinicalTrials.gov ↗ · MDS, AML, Adult	Phase 2	Not yet open	Ruijin Hospital	China
A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL NCT07522801 · ClinicalTrials.gov ↗ · LAL	Phase 2	Not yet open	Philippe ROUSSELOT	Germany, France, Spain, Netherlands, Poland, Czechia
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations NCT07738887 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 2	Not yet open	The Lymphoma Academic Research Organisation	France, Belgium
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL NCT07840976 · ClinicalTrials.gov ↗ · Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)	Phase 2	Not yet open	Institute of Hematology & Blood Diseases Hospital, China	China
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia NCT06387420 · ClinicalTrials.gov ↗ · ACUTE MYELOID LEUKEMIA; AML	Phase 1/2	Not yet open	Akeso	China
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia NCT07486726 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)	Phase 1/2	Not yet open	Shanghai Jiao Tong University School of Medicine	China
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients NCT07722767 · AML (Acute Myeloid Leukemia)	Phase 1	Not yet open	Cullinan Therapeutics Inc	USA
Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia NCT06841952 · ClinicalTrials.gov ↗ · AML, Adult	Not applicable	Not yet open	The First Affiliated Hospital of Soochow University	China
The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations NCT07632170 · ClinicalTrials.gov ↗ · Myeloid Tumors	Not applicable	Not yet open	Bing Han	China
VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML NCT07635485 · ClinicalTrials.gov ↗ · Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)	Not applicable	Not yet open	The First Affiliated Hospital of Soochow University	China
A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients NCT07762508 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT)	Not applicable	Not yet open	The First Affiliated Hospital of Soochow University	China
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients NCT06544109 · ClinicalTrials.gov ↗ · Acute Promyelocytic Leukemia	Phase 2/3	By invitation	The First Affiliated Hospital of Soochow University	China
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China NCT05144243 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 4	Active, closed	AbbVie	China
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy NCT02993523 · Acute Myeloid Leukemia (AML)	Phase 3	Active, closed	AbbVie	USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL NCT03336333 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	BeiGene	UK, USA, China, France, Spain, Italy, Belgium, Sweden, Poland, Austria, Czechia, Taiwan, Australia
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) NCT03462719 · Leukemia, Lymphocytic, Chronic, B-Cell	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, France, Spain, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Israel
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. NCT03539744 · Multiple Myeloma	Phase 3	Active, closed	AbbVie	UK, USA, China, Germany, France, Spain, Italy, Sweden, Denmark, Czechia, Turkey, Canada, Japan, South Korea, Singapore, Australia, Israel
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia NCT03701282 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia NCT03737981 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL NCT03836261 · Chronic Lymphocytic Leukemia	Phase 3	Active, closed	Acerta Pharma BV	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Austria, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial NCT03844048 · Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma	Phase 3	Active, closed	AbbVie	Ireland, UK, USA, China, France, Spain, Belgium, Sweden, Denmark, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Australia
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 NCT04229979 · Acute Myeloid Leukemia	Phase 3	Active, closed	Sellas Life Sciences Group	USA, India, Germany, France, Spain, Poland, Taiwan
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome NCT04401748 · Myelodysplastic Syndrome (MDS)	Phase 3	Active, closed	AbbVie	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) NCT04608318 · Chronic Lymphoid Leukemia	Phase 3	Active, closed	German CLL Study Group	Ireland, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Norway, Israel
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) NCT04965493 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	Loxo Oncology, Inc	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Czechia, Norway, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT05057494 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 3	Active, closed	AstraZeneca	USA, France, Spain, Poland, Czechia, Australia
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) NCT05183035 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 3	Active, closed	PedAL BCU, LLC	Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Canada, Japan, Australia, Israel
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) NCT06073821 · CLL	Phase 3	Active, closed	BeOne Medicines	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) NCT02899052 · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA, Spain, Australia
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT02966756 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)	Phase 2	Active, closed	AbbVie	China, Taiwan, Australia
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma NCT03314181 · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA, Germany, France, Denmark, Canada, Japan, Australia, Israel
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL NCT03580928 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL)	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A NCT03766763 · ClinicalTrials.gov ↗ · Chronic Lymphoid Leukemia	Phase 2	Active, closed	French Innovative Leukemia Organisation	France
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation NCT04082897 · ClinicalTrials.gov ↗ · CLL Transformation	Phase 2	Active, closed	Niguarda Hospital	Italy, Switzerland
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL NCT04515238 · Chronic Lymphoid Leukemia	Phase 2	Active, closed	German CLL Study Group	Germany
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL NCT04560322 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax NCT04763928 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	Gruppo Italiano Malattie EMatologiche dell'Adulto	Italy
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML NCT04801797 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma NCT04802590 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma	Phase 2	Active, closed	The Lymphoma Academic Research Organisation	France, Belgium
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. NCT05201066 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic	Phase 2	Active, closed	Novartis Pharmaceuticals	USA, China, Germany, France, Spain, Italy, Switzerland, Czechia, Turkey, Canada, Brazil, Japan, Australia
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm NCT05600894 · ClinicalTrials.gov ↗ · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia NCT05734495 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) NCT05768711 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia	Phase 2	Active, closed	Groupe Francophone des Myelodysplasies	France
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma NCT05864742 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma Refractory	Phase 2	Active, closed	Peter MacCallum Cancer Centre, Australia	Australia
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma NCT05951959 · Mantle Cell Lymphoma (MCL)	Phase 2	Active, closed	AstraZeneca	UK, USA, Spain, Poland, Canada, Brazil, Australia
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia NCT05963074 · Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA, France, Spain, Italy, Poland, Czechia, Canada
Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) NCT05996406 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax	Phase 2	Active, closed	Peking Union Medical College Hospital	China
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy NCT06384261 · Leukemia, Myeloid, Acute	Phase 2	Active, closed	OncoVerity, Inc	USA, Germany, Spain, Switzerland, Canada
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML NCT06429098 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	The First Affiliated Hospital of Soochow University	China
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy NCT06456463 · Acute Myeloid Leukemia	Phase 2	Active, closed	Stemline Therapeutics, Inc	USA, Australia, Israel
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period NCT06524375 · Chronic Lymphocytic Leukemia	Phase 2	Active, closed	Genentech, Inc	USA
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) NCT06629818 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia NCT06668558 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias	Spain
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML NCT06744556 · ClinicalTrials.gov ↗ · AML	Phase 2	Active, closed	Institute of Hematology & Blood Diseases Hospital, China	China
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) NCT07387471 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma	Phase 2	Active, closed	AbbVie	Japan
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic	Phase 1/2	Active, closed	Juno Therapeutics, a Subsidiary of Celgene	USA, Canada, Israel
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia NCT03504644 · ClinicalTrials.gov ↗ · Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma	Phase 1/2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma NCT03980171 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 1/2	Active, closed	Peter MacCallum Cancer Centre, Australia	Australia
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia NCT04086264 · Acute Myeloid Leukemia	Phase 1/2	Active, closed	AbbVie	UK, USA, Germany, France, Spain, Italy
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome NCT04623541 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome	Phase 1/2	Active, closed	Genmab	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Australia, Israel
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) NCT04657081 · Acute Myeloid Leukemia	Phase 1/2	Active, closed	Taiho Oncology, Inc	USA, Spain, Canada
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) NCT05182385 · ClinicalTrials.gov ↗ · ALL, Recurrent, Adult	Phase 1/2	Active, closed	Goethe University	Germany
Venetoclax in Patients With MDS or AML in Relapse After AHSCT NCT05226455 · ClinicalTrials.gov ↗ · MDS, AML	Phase 1/2	Active, closed	Groupe Francophone des Myelodysplasies	France
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies NCT05428969 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes	Phase 1/2	Active, closed	Faron Pharmaceuticals Ltd	UK, USA
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia NCT05520567 · Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia	Phase 1/2	Active, closed	Astellas Pharma Global Development, Inc	USA
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes NCT05782127 · ClinicalTrials.gov ↗ · Untreated Myelodysplastic Syndrome	Phase 1/2	Active, closed	Groupe Francophone des Myelodysplasies	France
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia NCT02890329 · ClinicalTrials.gov ↗ · Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related	Phase 1	Active, closed	National Cancer Institute (NCI)	Israel
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia NCT03041688 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	Phase 1	Active, closed	National Cancer Institute (NCI)	Israel
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia NCT04150887 · Leukemia, Myeloid, Acute	Phase 1	Active, closed	OncoVerity, Inc	USA, Germany, Poland, Switzerland, Canada
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies NCT04227847 · ClinicalTrials.gov ↗ · Myelodysplastic Syndrome, Acute Myeloid Leukemia	Phase 1	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA, Netherlands, Japan, Israel
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations NCT04603001 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)	Phase 1	Active, closed	Eli Lilly and Company	USA, China, Germany, France, Spain, Belgium, Canada, South Korea, Taiwan, Singapore, Australia, Israel
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia NCT05001828 · Acute Myeloid Leukemia, Adult	Phase 1	Active, closed	Polaris Group	USA
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies NCT05453903 · Leukemia, Myeloid, Acute	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA, Germany, France, Spain, Italy, Canada, Australia
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms NCT05455294 · ClinicalTrials.gov ↗ · Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis	Phase 1	Active, closed	Jacqueline Garcia, MD	Israel
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies NCT05753501 · Hematologic Cancer	Phase 1	Active, closed	AbbVie	UK, USA, Germany, France, Spain, Italy, Canada, Japan, Israel
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms NCT06651229 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms	Phase 1	Active, closed	Janssen Research & Development, LLC	France, Spain, Australia
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy NCT04282811 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia	Observational	Active, closed	Gruppo Italiano Malattie EMatologiche dell'Adulto	Italy
Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML NCT07318662 · ClinicalTrials.gov ↗ · MDS, CMML	Observational	Active, closed	Guangdong Provincial People's Hospital	China
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia NCT07187505 · ClinicalTrials.gov ↗ · Acute Promyelocytic Leukemia (APL)	Not applicable	Active, closed	Anhui Medical University	China
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma NCT04161248 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell	Early Phase 1	Active, closed	Canadian Cancer Trials Group	Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Venetoclax in the EU trials register (CTIS)

12 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Venetoclax. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab 2024-518858-17-00 · Neoplasms	Phase 2	Ongoing	AstraZeneca AB	Ireland + 5 more
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2 2026-525759-96-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Authorised	Centre Hospitalier Universitaire De Toulouse	France
EVITA - Epcoritamab plus Venetoclax plus Ibrutinib in patients with chronic lymphocytic leukemia with TP53 Alterations 2025-520893-20-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 2	Authorised	LYSARC	Belgium, France
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements 2026-526409-14-00 · Neoplasms	Phase 1	Authorised	Charm Therapeutics Limited	France, Germany, Spain + 2 more
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations 2026-525763-40-00 · Hemic and Lymphatic Diseases	Phase 2	Authorised	French Innovative Leukemia Organization (F.I.L.O.)	France
FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia 2026-526961-76-00 · Hemic and Lymphatic Diseases	Phase 1	Ongoing	Karolinska University Hospital	Sweden
Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice 2025-524795-35-00 · Hemic and Lymphatic Diseases	Phase 4	Authorised	Uniwersytet Medyczny W Lublinie	Poland
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL 2024-516570-30-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 2	Authorised	Centre Hospitalier De Versailles	Germany, France, Czechia + 2 more
Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) 2024-513917-11-01 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 1	Authorised	Uniwersytet Medyczny W Lublinie	Poland
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone 2025-524308-31-00 · CTIS ↗ · Neoplasms	Phase 2	Ongoing	Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe	Italy, Spain
Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN 2024-517130-17-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Centre Hospitalier Universitaire De Bordeaux	France
Venetoclax as treatment of acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation in a Phase-II dose escalation pilot study. 2025-520545-74-00 · CTIS ↗ · Immune System Diseases	Phase 2	Ongoing	Medical University Of Vienna	Austria

Venetoclax across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Venetoclax on the HPRA medicines list.

Venclyxto 10 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/16/1138/001-002
Venclyxto 100 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/16/1138/005-007
Venclyxto 50 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/16/1138/003-004

All 3 Irish products →

Supply shortages

No entry for Venetoclax in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Venetoclax

191 conditions

Acute Myeloid Leukemia44 Chronic Lymphocytic Leukemia17 Acute Myeloid Leukemia (AML)13 Small Lymphocytic Lymphoma11 Myelodysplastic Syndromes10 AML10 Leukemia, Myeloid, Acute9 Multiple Myeloma6Chronic Lymphocytic Leukemia (CLL)6AML, Adult6Chronic Myelomonocytic Leukemia5MDS5

All 191 conditions

Condition (as registered)	Trials
Acute Myeloid Leukemia	44
Chronic Lymphocytic Leukemia	17
Acute Myeloid Leukemia (AML)	13
Small Lymphocytic Lymphoma	11
Myelodysplastic Syndromes	10
AML	10
Leukemia, Myeloid, Acute	9
Multiple Myeloma	6
Chronic Lymphocytic Leukemia (CLL)	6
AML, Adult	6
Chronic Myelomonocytic Leukemia	5
MDS	5
Leukemia, Lymphocytic, Chronic, B-Cell	4
Waldenstrom Macroglobulinemia	4
Small Lymphocytic Lymphoma (SLL)	3
Acute Lymphoblastic Leukemia	3
Chronic Lymphoid Leukemia	3
CLL	3
Mantle Cell Lymphoma (MCL)	3
Leukemia	3
Acute Myeloid Leukemia, in Relapse	3
Childhood Leukemia, Acute Lymphoblastic	3
Acute Lymphoblastic Leukemia, Adult	3
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent	2
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	2
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory	2
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	2
Myelodysplastic Syndrome (MDS)	2
Lymphoma, Small Lymphocytic	2
Relapsed/Refractory AML	2
Myelodysplastic Syndrome	2
Refractory AML	2
Leukemia, Myeloid	2
Acute Myeloid Leukemia, Adult	2
Acute Myeloid Leukemia Refractory	2
Myeloid Malignancy	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Myelodysplastic Neoplasms	2
Relapse Acute Myeloid Leukemia	2
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	2
Chronic Myeloid Leukemia	2
Light Chain (AL) Amyloidosis	2
CLL/SLL	2
Secondary Acute Myeloid Leukemia	2
Mantle Cell Lymphoma	2
Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm	2
Acute Myeloid Leukemia Post Cytotoxic Therapy	2
Acute Myeloid Leukemia, Myelodysplasia-Related	2
Lymphoplasmacytic Lymphoma	2
Recurrent Acute Myeloid Leukemia	2
Refractory Acute Myeloid Leukemia	2
Non-Hodgkin's Lymphoma	1
Acute Lymphoblastic Leukemia, in Relapse	1
Leukemia, Lymphocytic, Acute	1
Haematological Malignancy	1
Non Hodgkin Lymphoma	1
Leukemia, Chronic Lymphocytic	1
Small-Cell Lymphoma	1
Hematologic Cancer	1
Myelodysplastic Syndrome/Neoplasm	1
Chronic Myelomonocytic Leukemia (CMML)	1
Myeloproliferative Neoplasms (MPNs)	1
Multiple Myeloma in Relapse	1
Multiple Myeloma, Refractory	1
Relapsed/Refractory Chronic Lymphocytic Leukemia	1
Richter's Syndrome	1
Treatment-naïve High Risk Chronic Lymphocytic Leukemia	1
Relapsed Adult AML	1
Myelodysplastic Syndrome With Excess Blasts-2	1
Mixed Lineage Leukemia Gene Mutation	1
AML With Mutated NPM1	1
Leukemia, Myelomonocytic, Chronic	1
Preleukemia	1
AML (Acute Myeloid Leukemia)	1
FLT3-mutated Acute Myeloid Leukemia	1
Hematologic Malignancies	1
B-cell Lymphoma	1
Cancer	1
Myelodysplastic Syndrome Acute Myeloid Leukemia	1
Higher-risk Myelodysplastic Syndromes	1
Relapsed/Refractory Acute Myeloid Leukaemia	1
APL	1
Acute T Lymphpblastic Leukemia/Lymphoma	1
Precursor B-Cell Lymphoblastic Leukemia	1
Acute Monocytic Leukemia	1
Newly Diagnosed	1
FLT3 Gene Mutation	1
Elderly	1
ETP-ALL	1
Hypoplastic Acute Myeloid Leukemia	1
Secondary AML (Adult)	1
Amyloidosis; Systemic	1
AL Amyloidosis	1
Transplantation	1
MRD	1
Adult T-cell Leukemia/Lymphoma	1
Acute Leukemia of Ambiguous Lineage	1
AML (Acute Myelogenous Leukemia)	1
Acute Lymphoblastic Leukemia ALL	1
B Cell Acute Lymphoblastic Leukemia (B-ALL)	1
Newly Diagnosed Acute Myeloid Leukemia (AML)	1
Elderly Patients	1
Myeloid Tumors	1
Philadelphia Chromosome Negative ALL	1
Leukemia, Myeloid, Acute(AML)	1
Hematopoietic Stem Cell Transplantation (HSCT)	1
Elderly Patients (60-75 Years)	1
CEBPA Mutation	1
Unfit, New-diagnosis AML	1
Early T Acute Lymphoblastic Leukemia	1
T-Acute Lymphoblastic Leukemia	1
Mixed Phenotype Acute Leukemia, T/Myeloid, Nos	1
T-cell Acute Lymphoblastic Leukemia	1
Relapse	1
Philadelphia Positive Acute Lymphoblastic Leukemia	1
Venentoclax	1
Myeloid Malignancies	1
Conditioning	1
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma	1
First Line Therapy	1
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	1
AML, Childhood	1
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	1
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)	1
CMML	1
CCND1 Translocation	1
Venetoclax	1
Ph+ ALL	1
Refractory Acute Myeloid Leukemia (AML)	1
Precursor B-Cell Acute Lymphoblastic Leukemia	1
Acute Promyelocytic Leukemia (APL)	1
Ann Arbor Stage II Follicular Lymphoma	1
Grade 1 Follicular Lymphoma	1
Ann Arbor Stage III Follicular Lymphoma	1
Ann Arbor Stage IV Follicular Lymphoma	1
Acute Promyelocytic Leukemia	1
Ph-Like	1
Refractory	1
Relapsed	1
CML,Blast Phase	1
ACUTE MYELOID LEUKEMIA; AML	1
Relapsed/Refractory Acute Myeloid Leukemia	1
Acute Myeloid Leukemia (AML) in Remission	1
High-Risk Acute Myeloid Leukemia	1
High-Risk Myelodysplastic Syndromes	1
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)	1
ALL, Recurrent, Adult	1
Treatment Naive	1
AML - Acute Myeloid Leukemia	1
LAL	1
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	1
Leukemia, B-Cell, Chronic	1
Untreated Myelodysplastic Syndrome	1
HIV-1	1
Relapse Leukemia	1
Refractory Leukemia	1
CLL Transformation	1
HIV-1-infection	1
Metastatic Colorectal Cancer	1
Myeloproliferative Neoplasm	1
Myelodysplastic Syndrome With Excess Blasts	1
Myelodysplastic/Myeloproliferative Neoplasm	1
Lymphoma, B-Cell	1
Diffuse Large B-Cell Lymphoma	1
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Double-Expressor Lymphoma	1
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Recurrent Adult Lymphoblastic Lymphoma	1
Recurrent B Acute Lymphoblastic Leukemia	1
Recurrent B Lymphoblastic Lymphoma	1
Recurrent T Acute Lymphoblastic Leukemia	1
Core Binding Factor Acute Myeloid Leukemia	1
T Lymphoblastic Leukemia/Lymphoma	1
Mantle Cell Lymphoma Refractory	1
Small Cell Lung Cancer ( SCLC )	1
Neuroendocrine Cancer	1
Malignant Pleural Mesotheliomas (Mpm)	1
Synovial Sarcomas	1
Follicular Lymphoma	1
Lymphoma	1
Marginal Zone Lymphoma	1
MZL	1
Refractory Lymphoma	1
Myelofibrosis	1
Acute Myeloid Leukaemia (AML)	1
Lymphoma, Mantle-Cell	1
Relapsed Acute Myeloid Leukemia	1
Minimal Residual Disease	1
Previously Treated Myelodysplastic Syndrome	1
Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related	1
Recurrent Myelodysplastic Syndrome	1

By country register

Register	Trials	Recruiting
Clinical trials in China	101	71
Clinical trials in USA	55	22
Clinical trials in France	49	19
Clinical trials in Spain	48	20
Clinical trials in Germany	42	20
Clinical trials in Israel	42	15
Clinical trials in Australia	37	14
Clinical trials in Canada	36	14
Clinical trials in Italy	34	15
Clinical trials in UK	27	14
Clinical trials in Belgium	25	12
Clinical trials in Poland	25	9
Clinical trials in Czechia	22	7
Clinical trials in Denmark	21	10
Clinical trials in Netherlands	20	11
Clinical trials in Japan	19	6
Clinical trials in South Korea	19	10
Clinical trials in Sweden	16	6
Clinical trials in Austria	16	8
Clinical trials in Mexico	16	10
Clinical trials in Brazil	15	8
Clinical trials in Taiwan	15	6
Clinical trials in Turkey	11	3
Clinical trials in Norway	9	4
Clinical trials in Switzerland	8	1
Clinical trials in Ireland	7	4
Clinical trials in Portugal	6	3
Clinical trials in Singapore	4	1
Clinical trials in Egypt	3	3
Clinical trials in India	2	1
EU register (CTIS)	12	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Venetoclax trials

How many clinical trials are testing Venetoclax?

216 current trials in our China, USA, France, Spain, Germany, Israel, Australia, Canada, Italy, UK, Belgium, Poland, Czechia, Denmark, Netherlands, Japan, South Korea, Sweden, Austria, Mexico, Brazil, Taiwan, Turkey, Norway, Switzerland, Ireland, Portugal, Singapore, Egypt and India registers name Venetoclax (also registered as ABT-199) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Venetoclax trials recruiting patients?

Yes. 130 of the 216 trials are recruiting: 71 with sites in China, 22 with sites in USA, 19 with sites in France, 20 with sites in Spain, 20 with sites in Germany, 15 with sites in Israel, 14 with sites in Australia, 14 with sites in Canada, 15 with sites in Italy, 14 with sites in UK, 12 with sites in Belgium, 9 with sites in Poland, 7 with sites in Czechia, 10 with sites in Denmark, 11 with sites in Netherlands, 6 with sites in Japan, 10 with sites in South Korea, 6 with sites in Sweden, 8 with sites in Austria, 10 with sites in Mexico, 8 with sites in Brazil, 6 with sites in Taiwan, 3 with sites in Turkey, 4 with sites in Norway, 1 with sites in Switzerland, 4 with sites in Ireland, 3 with sites in Portugal, 1 with sites in Singapore, 3 with sites in Egypt and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Venetoclax clinical trials?

Institute of Hematology & Blood Diseases Hospital, China (22), AbbVie (15), National Cancer Institute (NCI) (13) and The First Affiliated Hospital of Soochow University (12), among 105 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Venetoclax clinical trials in Ireland?

Yes. 7 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Venetoclax licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Venetoclax, for example Venclyxto 10 mg film-coated tablets (AbbVie Deutschland GmbH & Co. KG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Venetoclax shortage?

Not in the lists we track: Venetoclax has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Venetoclax works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Venetoclax works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Venetoclax (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.